Cerebrotendinous xanthomatosis: A rare cause of bilateral Achilles tendon swelling and ataxia

Journal of Bone and Joint Surgery

Volumn 88, Issue 6, 2006, Pages 1340-1344

  Brodsky, James W ^a   Beischer, Andrew D ^a   East, Cara ^b   Soltero, Elizabeth ^b   Tint, G Stephen ^c   Salen, Gerald ^c   Silverman, Julie ^a  

^a Clinical Cardiovascular Research Center ^*  (United States)

^b Cardiovascular Research   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHENODEOXYCHOLIC ACID; STEROL 27 HYDROXYLASE; URSODEOXYCHOLIC ACID;

ACHILLES TENDON; ADULT; ARTICLE; ATAXIA; BIOPSY; CASE REPORT; CEREBROTENDINOUS XANTHOMATOSIS; CYP27 GENE; DISEASE COURSE; EARLY DIAGNOSIS; FOOT ORTHOSIS; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIPIDOSIS; MALE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

EID: 33744802343     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.E.00872     Document Type: Article

References (20)

1. Lee MH, Hazard S, Carpten JD, Yi S, Cohen J, Gerhardt GT, Salen G, Patel SB. Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J Lipid Res. 2001;42:159-69.
2. Bjorken I, Boberg KM, Leitersdoef E. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: Scriver CR, Beaudet AL, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p 2970-8.
3. Pardo J, Prieto JM, Rodriguez JR, Vadillo J, Dapena MD, Noya M. [Magnetic resonance of the brain and Achilles tendon in cerebrotendinous xanthomatosis]. Neurologia. 1993;8:268-70. Spanish.
4. van Bogaert L, Scherer HJ, Epstein E. Une forme cérébrale de la cholestérinose généralisée: (type particulier de lipidose à cholestérine). Paris: Masson et Cie; 1937.
5. Meiner V, Meiner Z, Reshef A, Bjorktiem I, Leitersdorf E. Cerebrotendinous xanthomatosis: molecular diagnosis enables presymptomatic detection of a treatable disease. Neurology. 1994;44:288-90.
6. Berginer VM, Shany S, Alkalay D, Berginer J, Dekel S, Salen G, Tint GS, Gazit D. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism. 1993;42:69-74.
7. Chang WN, Lui CC. Failure in the treatment of long-standing osteoporosis in cerebrotendinous xanthomatosis. J Formos Med Assoc. 1997;96:225-7.
8. Kuriyama M, Fujiyama J, Kubota R, Nakagawa M, Osame M. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism. 1993;42:1497-8.
9. Kuritzky A, Berginer VM, Korczyn AD. Peripheral neuropathy in cerebrotendinous xanthomatosis. Neurology. 1979;29:880-1.
10. Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumuro K, Kasama T, Fukuda K, Kuramoto T, Hoshita T, Seyama Y, Okatu Y, Osame M. Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neural Sci. 1991;102:225-32.
11. Katz DA, Scheinberg L, Horoupian DS, Salen G. Peripheral neuropathy in cerebrotendinous xanthomatosis. Arch Neurol. 1985;42:1008-10.
12. Cruysberg JR, Wevers RA, van Engelen BG, Pinckers A, van Spreeken A, Tolboom JJ. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol. 1995;120:597-604.
13. Lussier-Cacan S, Cantin M, Roy CC, Sniderman AD, Nestruck AC, Davignon J. Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia. Clin Invest Med. 1986;9:94-9.
14. Bouwes Bavinck JN, Vermeer BJ, Gevers Leuven JA, Koopman BJ, Wolthers BG. Capillary gas chromatography of urine samples in diagnosing cerebrotendinous xanthomatosis. Arch Dermatol. 1986;122:1269-72.
15. Wolthers BG, Volmer M, van der Molen J, Koopman BJ, de Jager AE, Waterreus RJ. Diagnosis of cerebrotendinous xanthomatosis (CTX) and effect of chenodeoxycholic acid therapy by analysis of urine using capillary gas chromatography. Clin Chim Acta. 1983;131:53-65.
16. Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism. 1991;40:741-6.
17. Kuriyama M, Tokimura Y, Fujiyama J, Utatsu Y, Osame M. Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. J Neurol Sci. 1994;125:22-8.
18. Watts GF, Mitchell WD, Bending JJ, Reshef A, Leitersdorf E. Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy. QJM. 1996;89:55-63.
19. Peynet J, Laurent A, De Liege P, Lecoz P, Gambert P, Legrand A, Mikol J, Warnet A. Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. Neurology. 1991;41:434-6.
20. Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Naurosurg. 1987;89:169-75.